Floatz logo

Carboplatin

Pyrotinib

First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pyrotinib cohort.

Asset / SponsorPhaseRating
Vinorelbine
Sun Yat-sen University
Phase 2CCC
Pyrotinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
TRASTUZUMAB
First Affiliated Hospital of Zhejiang University
Phase 2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →